Skip to main content


Page 2 of 104

  1. This study aimed to investigate the contralateral breast cancer (CBC) recurrence rate in Korean breast cancer patients according to their BRCA1/2 germline mutation status, focusing particularly on the CBC recurre...

    Authors: Eunhye Kang, Ji-Jung Jung, Changjin Lim, Hong-Kyu Kim, Han-Byoel Lee, Wonshik Han and Hyeong-Gon Moon
    Citation: Breast Cancer Research 2024 26:14
  2. Endocrine therapy resistance in hormone receptor-positive/HER2-negative (HR+/HER2−) breast cancer (BC) is a significant clinical challenge that poses several unmet needs in the management of the disease. This ...

    Authors: Jieun Park, Eun Sol Chang, Ji-Yeon Kim, Chaithanya Chelakkot, Minjung Sung, Ji-Young Song, Kyungsoo Jung, Ji Hye Lee, Jun Young Choi, Na Young Kim, Hyegyeong Lee, Mi-Ran Kang, Mi Jeong Kwon, Young Kee Shin, Yeon Hee Park and Yoon-La Choi
    Citation: Breast Cancer Research 2024 26:13
  3. Pathological complete response (pCR) is associated with favorable prognosis in patients with triple-negative breast cancer (TNBC). However, only 30–40% of TNBC patients treated with neoadjuvant chemotherapy (N...

    Authors: Timothy B. Fisher, Geetanjali Saini, T. S. Rekha, Jayashree Krishnamurthy, Shristi Bhattarai, Grace Callagy, Mark Webber, Emiel A. M. Janssen, Jun Kong and Ritu Aneja
    Citation: Breast Cancer Research 2024 26:12
  4. Human breast cancer most frequently originates within a well-defined anatomical structure referred to as the terminal duct lobular unit (TDLU). This structure is endowed with its very own lobular fibroblasts r...

    Authors: Mikkel Morsing Bagger, Jonas Sjölund, Jiyoung Kim, Katharina Theresa Kohler, René Villadsen, Abbas Jafari, Moustapha Kassem, Kristian Pietras, Lone Rønnov-Jessen and Ole William Petersen
    Citation: Breast Cancer Research 2024 26:11
  5. Triple-negative breast cancer (TNBC) remains the most challenging subtype of breast cancer and lacks definite treatment targets. Aerobic glycolysis is a hallmark of metabolic reprogramming that contributes to ...

    Authors: Zi-Mei Peng, Xiao-Jian Han, Tao Wang, Jian-Jun Li, Chun-Xi Yang, Fang-Fang Tou and Zhen Zhang
    Citation: Breast Cancer Research 2024 26:10
  6. This study aimed to evaluate the prognostic role of the baseline neutrophil/lymphocyte ratio (NLR) in HER2-positive metastatic breast cancer (MBC) patients treated with trastuzumab/pertuzumab.

    Authors: Nianhua Ding, Jian Pang, Xuan Liu, Xiongbin He, Wei Zhou, Haiqing Xie, Jianqi Feng, Guo Wang, Jie Tang, Jing Cao, Liying He, Yingjian He, Shouman Wang and Zhi Xiao
    Citation: Breast Cancer Research 2024 26:9
  7. To understand the dynamics that limit use of risk-management options by women at high risk of breast cancer, there is a critical need for research that focuses on patient perspectives. Prior research has left ...

    Authors: Tasleem J. Padamsee, Christina Bijou, Paige Swinehart-Hord, Megan Hils, Anna Muraveva, Rachel J. Meadows, Kate Shane-Carson, Lisa D. Yee, Celia E. Wills and Electra D. Paskett
    Citation: Breast Cancer Research 2024 26:8
  8. Generalizability of predictive models for pathological complete response (pCR) and overall survival (OS) in breast cancer patients requires diverse datasets. This study employed four machine learning models to...

    Authors: Kevin Dell’Aquila, Abhinav Vadlamani, Takouhie Maldjian, Susan Fineberg, Anna Eligulashvili, Julie Chung, Richard Adam, Laura Hodges, Wei Hou, Della Makower and Tim Q. Duong
    Citation: Breast Cancer Research 2024 26:7
  9. Reports of dual carriers of pathogenic BRCA1 variants in trans are extremely rare, and so far, most individuals have been associated with a Fanconi Anemia-like phenotype.

    Authors: Ines Block, Àngels Mateu-Regué, Thi Tuyet Nhu Do, Ieva Miceikaite, Daniel Sdogati, Martin J. Larsen, Qin Hao, Henriette Roed Nielsen, Susanne E. Boonen, Anne-Bine Skytte, Uffe Birk Jensen, Louise K. Høffding, Arcangela De Nicolo, Alessandra Viel, Emma Tudini, Michael T. Parsons…
    Citation: Breast Cancer Research 2024 26:6
  10. Triple-negative breast cancer (TNBC) is highly aggressive with limited available treatments. Stromal cells in the tumor microenvironment (TME) are crucial in TNBC progression; however, understanding the molecu...

    Authors: Stephanie J. Hachey, Christopher J. Hatch, Daniela Gaebler, Aneela Mocherla, Kevin Nee, Kai Kessenbrock and Christopher C. W. Hughes
    Citation: Breast Cancer Research 2024 26:5
  11. Dysregulated Notch signalling contributes to breast cancer development and progression, but validated tools to measure the level of Notch signalling in breast cancer subtypes and in response to systemic therap...

    Authors: Eike-Benjamin Braune, Felix Geist, Xiaojia Tang, Krishna Kalari, Judy Boughey, Liewei Wang, Roberto A. Leon-Ferre, Antonino B. D’Assoro, James N. Ingle, Matthew P. Goetz, Julian Kreis, Kang Wang, Theodoros Foukakis, Anita Seshire, Dirk Wienke and Urban Lendahl
    Citation: Breast Cancer Research 2024 26:4
  12. Neoadjuvant endocrine therapy (NET) in oestrogen receptor-positive (ER+) /HER2-negative (HER2-) breast cancer allows real-time evaluation of drug efficacy as well as investigation of the biological and molecul...

    Authors: Joanna I. López-Velazco, Sara Manzano, María Otaño, Kepa Elorriaga, Núria Bultó, Julio Herrero, Ainhara Lahuerta, Virginia Segur, Isabel Álvarez-López, Maria M. Caffarel and Ander Urruticoechea
    Citation: Breast Cancer Research 2024 26:3
  13. Previous work in European ancestry populations has shown that adding a polygenic risk score (PRS) to breast cancer risk prediction models based on epidemiologic factors results in better discriminatory perform...

    Authors: Gary R. Zirpoli, Ruth M. Pfeiffer, Kimberly A. Bertrand, Dezheng Huo, Kathryn L. Lunetta and Julie R. Palmer
    Citation: Breast Cancer Research 2024 26:2
  14. Despite radiotherapy ability to significantly improve treatment outcomes and survival in triple-negative breast cancer (TNBC) patients, acquired resistance to radiotherapy poses a serious clinical challenge. P...

    Authors: Jinqiu Tao, Cailin Xue, Meng Cao, Jiahui Ye, Yulu Sun, Hao Chen, Yinan Guan, Wenjie Zhang, Weijie Zhang and Yongzhong Yao
    Citation: Breast Cancer Research 2024 26:1
  15. Allostatic load (AL) reflects the collective load of chronic stress during lifetime. Previous studies have shown that higher AL is associated with poor clinical outcomes among breast cancer patients. However, ...

    Authors: Yufan Guan, Jie Shen, Juan Lu, Bernard F. Fuemmeler, Lisa S. Shock and Hua Zhao
    Citation: Breast Cancer Research 2023 25:155
  16. The role of HER2 amplification level in predicting the effectiveness of HER2-directed therapies has been established. However, its association with survival outcomes in advanced HER2-positive breast cancer tre...

    Authors: Jeongmin Seo, Jiwon Koh, Dae-Won Lee, Jinyong Kim, Han Suk Ryu, Kyung-Hun Lee, Tae-Yong Kim and Seock-Ah Im
    Citation: Breast Cancer Research 2023 25:154
  17. Invasive lobular breast carcinomas (ILC) have different histological features compared to non-special type carcinomas (NST), but the effect of histological subtypes on survival is controversial. In this study,...

    Authors: Davut Dayan, Stefan Lukac, Brigitte Rack, Florian Ebner, Visnja Fink, Elena Leinert, Kristina Veselinovic, Sabine Schütze, Ziad El Taie, Wolfgang Janni and Thomas W. P. Friedl
    Citation: Breast Cancer Research 2023 25:153
  18. The homologous recombination (HR) repair pathway for DNA damage, particularly the BRCA1 and BRCA2 genes, has become a target for cancer therapy, with poly ADP-ribose polymerase (PARP) inhibitors showing significa...

    Authors: Han-Fang Cheng, Yi-Fang Tsai, Chun-Yu Liu, Chih-Yi Hsu, Pei-Ju Lien, Yen-Shu Lin, Ta-Chung Chao, Jiun-I. Lai, Chin-Jung Feng, Yen-Jen Chen, Bo-Fang Chen, Jen-Hwey Chiu, Ling-Ming Tseng and Chi-Cheng Huang
    Citation: Breast Cancer Research 2023 25:152
  19. Triple-negative breast cancer (TNBC) represents the most challenging subtype of breast cancer. Studies have implicated an upregulation of lipid synthesis pathways in the initiation and progression of TNBC. Tar...

    Authors: Pan Hu, Peiyi Zhou, Tieyun Sun, Dingkang Liu, Jun Yin and Lubin Liu
    Citation: Breast Cancer Research 2023 25:151
  20. Epidemiologic data on insecticide exposures and breast cancer risk are inconclusive and mostly from high-income countries. Using data from 1071 invasive pathologically confirmed breast cancer cases and 2096 co...

    Authors: Naomie Olivos, Jim E. Banta, Rhonda Spencer-Hwang, Daniel Ansong, Laura E. Beane Freeman, Joe-Nat Clegg-Lamptey, Beatrice Wiafe-Addai, Lawrence Edusei, Ernest Adjei, Nicholas Titiloye, Florence Dedey, Francis Aitpillah, Joseph Oppong, Verna Vanderpuye, Ernest Osei-Bonsu, Thomas U. Ahearn…
    Citation: Breast Cancer Research 2023 25:150
  21. Based on the molecular expression of cancer cells, molecular subtypes of breast cancer have been applied to classify patients for predicting clinical outcomes and prognosis. However, further evidence is needed...

    Authors: Shih-Kai Hung, Hsuan-Ju Yang, Moon-Sing Lee, Dai-Wei Liu, Liang-Cheng Chen, Chia-Hui Chew, Chun-Hung Lin, Cheng-Hung Lee, Szu-Chin Li, Chung-Lin Hong, Chih-Chia Yu, Ben-Hui Yu, Feng-Chun Hsu, Wen-Yen Chiou and Hon-Yi Lin
    Citation: Breast Cancer Research 2023 25:149
  22. Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype and leads to the poorest patient outcomes despite surgery and chemotherapy treatment. Exploring new molecular mechanisms of TNB...

    Authors: Zheqiong Tan, Pragney Deme, Keerti Boyapati, Britt S. R. Claes, Annet A. M. Duivenvoorden, Ron M. A. Heeren, Caitlin M. Tressler, Norman James Haughey and Kristine Glunde
    Citation: Breast Cancer Research 2023 25:148
  23. Women with dense breasts have an increased risk of breast cancer. However, breast density is measured with variability, which may reduce the reliability and accuracy of its association with breast cancer risk....

    Authors: Emma C. Atakpa, Diana S. M. Buist, Erin J. Aiello Bowles, Jack Cuzick and Adam R. Brentnall
    Citation: Breast Cancer Research 2023 25:147
  24. In breast cancer, the advent of anti-HER2 therapies has made HER2+ tumors a highly relevant subgroup. However, the exact characteristics which prohibit clinical response to anti-HER2 therapies and drive diseas...

    Authors: Noortje Verschoor, Marcel Smid, Agnes Jager, Stefan Sleijfer, Saskia M. Wilting and John W. M. Martens
    Citation: Breast Cancer Research 2023 25:145
  25. Breast cancer stem cells (BCSCs) are resistant to standard therapies, facilitate tumor dissemination, and contribute to relapse and progression. Super-enhancers are regulators of stemness, and BET proteins, wh...

    Authors: Deeksha Sharma, Cody G. Hager, Li Shang, Lam Tran, Yongyou Zhu, Aihui Ma, Brian Magnuson, Matthew W. Lesko, Max S. Wicha and Monika L. Burness
    Citation: Breast Cancer Research 2023 25:144
  26. As in most solid cancers, the emergence of cells with oncogenic mutations in the mammary epithelium alters the tissue homeostasis. Some soluble factors, such as TGFβ, potently modify the behavior of healthy st...

    Authors: Héctor Franco-Valls, Elsa Tusquets-Uxó, Laura Sala, Maria Val, Raúl Peña, Alessandra Iaconcig, Álvaro Villarino, Martín Jiménez-Arriola, Pere Massó, Juan L. Trincado, Eduardo Eyras, Andrés F. Muro, Jorge Otero, Antonio García de Herreros and Josep Baulida
    Citation: Breast Cancer Research 2023 25:143
  27. Invasive breast cancer patients are increasingly being treated with neoadjuvant chemotherapy; however, only a fraction of the patients respond to it completely. To prevent overtreatment, there is an urgent nee...

    Authors: Witali Aswolinskiy, Enrico Munari, Hugo M. Horlings, Lennart Mulder, Giuseppe Bogina, Joyce Sanders, Yat-Hee Liu, Alexandra W. van den Belt-Dusebout, Leslie Tessier, Maschenka Balkenhol, Michelle Stegeman, Jeffrey Hoven, Jelle Wesseling, Jeroen van der Laak, Esther H. Lips and Francesco Ciompi
    Citation: Breast Cancer Research 2023 25:142
  28. Window-of-opportunity (WOO) studies provide insights into the clinical activity of new drugs in breast cancer.

    Authors: Mario Campone, François-Clément Bidard, Patrick Neven, Lei Wang, Bin Ling, Yvonne Dong, Gautier Paux, Christina Herold and Ugo De Giorgi
    Citation: Breast Cancer Research 2023 25:141
  29. Considering the recent advancements in the treatment of breast cancer with low expression of human epidermal growth factor receptor 2 (HER2), we aimed to examine inter-laboratory variability in the assessment ...

    Authors: Kåre Nielsen, Michael Sode, Maj-Britt Jensen, Tobias Berg, Ann Knoop, Bent Ejlertsen and Anne-Vibeke Lænkholm
    Citation: Breast Cancer Research 2023 25:139
  30. To investigate combined MRI and 18F-FDG PET for assessing breast tumor metabolism/perfusion mismatch and predicting pathological response and recurrence-free survival (RFS) in women treated for breast cancer.

    Authors: Anum S. Kazerouni, Lanell M. Peterson, Isaac Jenkins, Alena Novakova-Jiresova, Hannah M. Linden, Julie R. Gralow, David M. Hockenbery, David A. Mankoff, Peggy L. Porter, Savannah C. Partridge and Jennifer M. Specht
    Citation: Breast Cancer Research 2023 25:138
  31. Despite a 40% reduction in breast cancer mortality over the last 30 years, not all groups have benefited equally from these gains. A consistent link between later stage of diagnosis and disparities in breast c...

    Authors: Jessica L. Webster, Neal D. Goldstein, Jennifer P. Rowland, Catherine M. Tuite and Scott D. Siegel
    Citation: Breast Cancer Research 2023 25:137
  32. Exposure to cytotoxic chemotherapy treatment may alter DNA methylation (DNAm) in breast cancer patients.

    Authors: Peh Joo Ho, Alexis Jiaying Khng, Benita Kiat-Tee Tan, Geok Hoon Lim, Su-Ming Tan, Veronique Kiak Mien Tan, Ryan Shea Ying Cong Tan, Elaine Hsuen Lim, Philip Tsau-Choong Iau, Ying Jia Chew, Yi Ying Lim, Mikael Hartman, Ern Yu Tan and Jingmei Li
    Citation: Breast Cancer Research 2023 25:136
  33. This study aimed to develop a novel combined immune score (CIS)-based model assessing prognosis in triple-negative breast cancer (TNBC).

    Authors: Ji Eun Choi, Jae Seok Lee, Min-Sun Jin, Ilias P. Nikas, Kwangsoo Kim, Sunah Yang, Soo Young Park, Jiwon Koh, Sohyeon Yang, Seock-Ah Im and Han Suk Ryu
    Citation: Breast Cancer Research 2023 25:134
  34. Authors: María C. Díaz Flaqué, Natalia M. Galigniana, Wendy Béguelin, Rocío Vicario, Cecilia J. Proietti, Rosalía Cordo Russo, Martín A. Rivas, Mercedes Tkach, Pablo Guzmán, Juan C. Roa, Esteban Maronna, Viviana Pineda, Sergio Muñoz, María Florencia Mercogliano, Eduardo H. Charreau, Patricio Yankilevich…
    Citation: Breast Cancer Research 2023 25:133
  35. Several studies have indicated that magnetic resonance imaging radiomics can predict survival in patients with breast cancer, but the potential biological underpinning remains indistinct. Herein, we aim to dev...

    Authors: Yunfang Yu, Wei Ren, Zifan He, Yongjian Chen, Yujie Tan, Luhui Mao, Wenhao Ouyang, Nian Lu, Jie Ouyang, Kai Chen, Chenchen Li, Rong Zhang, Zhuo Wu, Fengxi Su, Zehua Wang, Qiugen Hu…
    Citation: Breast Cancer Research 2023 25:132
  36. Mammary physiology is distinguished in containing adult stem/progenitor cells that are actively amending the breast tissue throughout the reproductive lifespan of women. Despite their importance in both mammar...

    Authors: Hakim Bouamar, Larry Esteban Broome, Kate Ida Lathrop, Ismail Jatoi, Andrew Jacob Brenner, Alia Nazarullah, Karla Moncada Gorena, Michael Garcia, Yidong Chen, Virginia Kaklamani and Lu-Zhe Sun
    Citation: Breast Cancer Research 2023 25:131
  37. Body fatness is a dynamic exposure throughout life. To provide more insight into the association between body mass index (BMI) and postmenopausal breast cancer, we aimed to examine the age at onset, duration, ...

    Authors: Marit Busund, Giske Ursin, Eiliv Lund, Tom Wilsgaard and Charlotta Rylander
    Citation: Breast Cancer Research 2023 25:130
  38. SND1 participates in tumorigenesis, tumour invasion and metastasis in different cancers. Previous studies have shown that SND1 can promote the invasion and migration of breast cancer cells. Triple-negative bre...

    Authors: Huibian Zhang, Min Gao, Wenying Zhao and Lin Yu
    Citation: Breast Cancer Research 2023 25:129
  39. Gremlin-1 (GREM1) and Gremlin-2 (GREM2) are bone morphogenetic protein antagonists that play important roles in organogenesis, tissue differentiation, and tissue homeostasis. Although GREM1 has been reported t...

    Authors: Jiwoo Jung, Na Hui Kim, Minji Kwon, Jayeon Park, Dayeon Lim, Youjin Kim, World Gil, Ye Hwang Cheong and Sin-Aye Park
    Citation: Breast Cancer Research 2023 25:128
  40. Mammogram risk scores based on texture and density defined by different brightness thresholds are associated with breast cancer risk differently and could reveal distinct information about breast cancer risk. ...

    Authors: Zhoufeng Ye, Tuong L. Nguyen, Gillian S. Dite, Robert J. MacInnis, Daniel F. Schmidt, Enes Makalic, Osamah M. Al-Qershi, Minh Bui, Vivienne F. C. Esser, James G. Dowty, Ho N. Trinh, Christopher F. Evans, Maxine Tan, Joohon Sung, Mark A. Jenkins, Graham G. Giles…
    Citation: Breast Cancer Research 2023 25:127
  41. Breast cancer metastasis is a complex, multi-step process, with high cellular heterogeneity between primary and metastatic breast cancer, and more complex interactions between metastatic cancer cells and other...

    Authors: Shikun Zhu, Mi Zhang, Xuexue Liu, Qing Luo, Jiahong Zhou, Miao Song, Jia Feng and Jinbo Liu
    Citation: Breast Cancer Research 2023 25:126
  42. An elevated number of circulating neutrophils is a poor prognostic factor for breast cancer, where evidence of bone marrow cancer-dependent priming is found. However, how early this priming is detectable remai...

    Authors: Anisha Ramessur, Bana Ambasager, Iker Valle Aramburu, Freddie Peakman, Kelly Gleason, Christoph Lehmann, Venizelos Papayannopoulos, Raoul Charles Coombes and Ilaria Malanchi
    Citation: Breast Cancer Research 2023 25:125
  43. Breast cancer (BC) is the most common malignant disease in female patients worldwide. In HER-2+ BC patients, trastuzumab therapy is associated with a better prognosis. However, many HER-2+ BC patients experien...

    Authors: Cuiwei Liu, Chong Lu, Lamu Yixi, Jiaxing Hong, Fang Dong, Shengnan Ruan, Ting Hu and Xiangwang Zhao
    Citation: Breast Cancer Research 2023 25:124
  44. Immunohistochemical (IHC) PD-L1 expression is commonly employed as predictive biomarker for checkpoint inhibitors in triple-negative breast cancer (TNBC). However, IHC evaluation methods are non-uniform and fu...

    Authors: Gudbjörg Sigurjonsdottir, Tommaso De Marchi, Anna Ehinger, Johan Hartman, Ana Bosch, Johan Staaf, Fredrika Killander and Emma Niméus
    Citation: Breast Cancer Research 2023 25:123
  45. High mammographic breast density (MBD) is a strong risk factor for breast cancer development, but the biological mechanisms underlying MBD are unclear. Lipids play important roles in cell differentiation, and ...

    Authors: Kayla R. Getz, Myung Sik Jeon, Chongliang Luo, Jingqin Luo and Adetunji T. Toriola
    Citation: Breast Cancer Research 2023 25:121
  46. Breast cancer is a complex and heterogeneous disease with distinct subtypes and molecular profiles corresponding to different clinical outcomes. Mouse models of breast cancer are widely used, but their relevan...

    Authors: Carson D. Broeker, Mylena M. O. Ortiz, Michael S. Murillo and Eran R. Andrechek
    Citation: Breast Cancer Research 2023 25:120

Annual Journal Metrics

  • 2022 Citation Impact
    7.4 - 2-year Impact Factor
    7.4 - 5-year Impact Factor
    1.764 - SNIP (Source Normalized Impact per Paper)
    2.408 - SJR (SCImago Journal Rank)

    2023 Speed
    20 days submission to first editorial decision for all manuscripts (Median)
    129 days submission to accept (Median)

    2023 Usage 
    1,561 Altmetric mentions